Shattuck Labs, Inc. (STTK) is a clinical-stage biotechnology company primarily engaged in the development of novel immunotherapeutic technologies for the treatment of cancer and autoimmune diseases. The company, headquartered in Durham, North Carolina, was founded in 2016 with the core vision to revolutionize the treatment of patients suffering from cancer and autoimmune diseases.
Shattuck Labs employs a groundbreaking approach to enhance the capability of the body's immune response to eradicate malignancies while reducing the negative impacts often associated with conventional therapies. Its proprietary Agonist Redirected Checkpoint (ARC) platform is at the core of their innovative strategy. ARC fusion proteins are designed to simultaneously target disease tissue and bolster the immune response, a ground-breaking methodology in the realm of immunotherapy.
Since its inception, STTK has made significant strides in biotechnology, holding an impressive array of ARC programs in development, with four therapies currently in clinical trials. These therapies aim to tackle a wide range of cancers, including but not limited to prostate cancer, breast cancer, and different forms of leukemia.
Beyond cancer treatments, Shattuck Labs is exploring the potential applications of its ARC platform for autoimmune diseases. They believe their technology holds the potential to treat a variety of conditions where the immune system attacks the body's own healthy cells, offering hope to millions of patients around the world.
Shattuck Labs' business strategy includes both the development of its in-house programs and strategic collaborations with pharmaceutical and biotechnology companies to leverage its unique technology. To date, STTK has successfully partnered with leading biotech firms to further their research, underscoring their commitment to transforming the landscape of therapeutic treatment.
Shattuck Labs went public in October 2020, listing on the NASDAQ under the ticker symbol STTK. Despite being a relatively young company, Shattuck Labs, Inc. has quickly established itself as a trailblazer in the field of immunotherapy, signaling immense growth potential and providing new hope to patients affected by various forms of cancer and autoimmune diseases.